I. Webb

发表

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

M. Grever, J. Wright, M. Shah, 2004, Clinical Cancer Research.

Adenovirus vector-based purging of multiple myeloma cells.

K. Anderson, M. Urashima, A. Ogata, 1998, Blood.

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.

D. Neuberg, M. Mihm, F. Hodi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

M. Mohty, P. Moreau, H. Avet-Loiseau, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

M. Gross, J. Hainsworth, L. Hart, 2014, Clinical Cancer Research.

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.

H. Scher, M. Galsky, M. Eisenberger, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.

J. Gribben, D. Neuberg, A. Freedman, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

G. Linette, F. Hodi, A. Sober, 2005, Clinical Cancer Research.

Risks, costs, and alternatives to platelet transfusions.

K. Anderson, I. Webb, K. Anderson, 1999, Leukemia & lymphoma.

Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections

G. Demetri, C. Wheeler, L. Ayash, 1996, Transfusion.

Expression of prostate specific membrane antigen in the neo-vasculature of non-prostate cancers.

R. Meyer, C. Sheehan, G. Gray, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial

P. Moreau, H. Avet-Loiseau, G. Marit, 2008 .

Anti-estrogens induce apoptosis of multiple myeloma cells.

M. Urashima, A. Ogata, G. Teoh, 1998, Blood.

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.

Catherine J. Wu, J. Ritz, D. Zahrieh, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer

D. Agus, D. Petrylak, R. Dreicer, 2007, Clinical Cancer Research.

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

I. Flinn, P. Richardson, P. Hari, 2009 .

Umbilical cord blood as a source of progenitor cells to reconstitute hematopoiesis.

I. Webb, 1997, Transfusion medicine reviews.

High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

P. Moreau, H. Avet-Loiseau, G. Marit, 2009 .

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

I. Flinn, G. Mulligan, P. Richardson, 2010 .

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

I. Flinn, A. Krishnan, P. Richardson, 2010, Leukemia.

Antibody-based therapeutics: Focus on prostate cancer

N. Bander, M. Rolfe, G. Gray, 2005, Cancer and Metastasis Reviews.

Graft-Versus-Host Disease

I. Webb, K. Anderson, 2001 .

Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With

D. Kufe, G. Teoh, D. Chauhan, 2008 .

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

D. Kufe, G. Teoh, D. Chauhan, 1999, Blood.

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

D. Neuberg, M. Mihm, F. Hodi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Prabhjot Kaur, C. Sheehan, G. Gray, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

F. Saad, N. Agarwal, D. Agus, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of high yield and purify of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma.

M. Jiroutek, D. Schott, I. Webb, 1999, Cytotherapy.

In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.

J. Ritz, R. Soiffer, M. Sugrue, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sequential CD34+ and CD4+ cell selection from leukapheresis components.

J. Daley, D. Schott, I. Webb, 1998, Journal of hematotherapy.

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

N. Bander, M. Morris, H. Scher, 2016, Urologic oncology.

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

I. Flinn, G. Mulligan, P. Richardson, 2012, Blood.

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

F. Saad, H. Scher, G. Heller, 2016, Clinical Cancer Research.

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

D. DeAngelo, R. Stone, P. Amrein, 2006 .

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

I. Flinn, A. Krishnan, P. Richardson, 2008 .

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.

C. Shapiro, G. Demetri, R. Gelman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

M. Gross, D. Agus, R. Dreicer, 2011 .

A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, H. Akaza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

previously untreated multiple myeloma of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in Randomized, multicenter, phase 2 study (EVOLUTION) of combinations

G. Mulligan, P. Richardson, P. Hari, 2012 .

A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM

I. Flinn, A. Krishnan, P. Richardson, 2009 .

Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.

J. Gribben, D. Neuberg, J. Ritz, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.